Oppenheimer Discusses Mindray Medical (MR)

Oppenheimer has a research report on Mindray Medical International Limited MR. It has a Perform rating on shares. In the research note Oppenheimer writes, "1) Management views the 16% revenue growth guidance in 2011 as deliverable, assuming double-digit growth in the developed markets, continued strong growth in emerging markets, flattish China tender growth and a gradual recovery in China non-tender business at mid-teens. 2) EPS growth will lag revenue growth due to increased SG&A and R&D. 3) Timing of the government's healthcare spending and VAT policy in 2011 are the key uncertainties. 4) Continues to evaluate M&A opportunities." Shares of MR lost 12 cents yesterday to close at $27.52.